SEATTLE, Nov. 08, 2017 (GLOBE NEWSWIRE) -- Cascadian Therapeutics, Inc. (NASDAQ:CASC), a clinical-stage biopharmaceutical ...
Investigative Sites Recognize Company’s Leadership in Advancing Clinical Research Through Collaborative Site Relationships RALEIGH, ...
Trial Continues on Scheduled Path with Expected Completion of Enrollment by June 2019NEW YORK, ...
